Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (17,926,026)	$ (7,141,905)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	560,220	694,836
Stock-based compensation	260,068	285,483
Loss (Gain) on revaluation of derivative liabilities, net	27,896	(2,176,982)
Interest converted to principal on convertible promissory notes	547,866	597,484
Provision for excess and obsolete inventory	492	60,353
Amortization of debt discount	2,094,335	718,918
Loss on extinguishment of debt	4,970,410
Issuance of warrants due to organic change	2,553,318
Change in operating assets and liabilities:
Accounts receivable	(41,854)	(14,607)
Inventories	131,151	111,953
Prepaid expenses and other assets	99,589	(15,019)
Accounts payable	248,105	(472,092)
Accrued payroll and related costs	1,055,332	(394,674)
Other accrued expenses	490,692	106,869
Net cash used in operating activities	(4,928,406)	(7,639,383)
Cash flows from investing activities:
Purchase of property and equipment	(41,906)	(41,262)
Net cash used in investing activities	(41,906)	(41,262)
Cash flows from financing activities:
Net proceeds from issuance of Series 1 convertible preferred stock, common stock and warrants	13,393,162
Net cash provided by financing activities	13,393,162
Effect of exchange rates on cash	(268,562)	178,358
Net increase (decrease) in cash and cash equivalents	8,154,288	(7,502,287)
Cash and cash equivalents at beginning of the period	6,328,753	15,117,172
Cash and cash equivalents at end of the period	14,483,041	7,614,885
Supplemental disclosures of cash flow information:
Cash paid for interest	4,341
Cash paid for income taxes	26,182	32,614
Cash (received) for income taxes	(1,051)	(25,539)
Supplemental disclosure of non-cash investing and financing activities:
Exchange of convertible promissory notes forcommon stock and Series 1 convertible preferred stock	6,035,360
Exchange of Series A-1 convertible preferred stock for common stock and Series 1 convertible preferred stock	9,838,569
Issuance of warrants to placement agent	1,147,021
Accretion on Series 1 convertible preferred stock associated with beneficial conversion feature	$ 702,970